NAMS 250117 7.50C (NAMS250117C7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

NAMS250117C7500

Watchlist

18.00
0.000.00%

15min DelayClose Jan 10 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Express News | Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 35.34 Million in Common Stocks
Moomoo NewsJan 10 16:33 ET
NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT &...
BenzingaJan 10 08:13 ET
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
GlobeNewswireJan 10 08:00 ET
Express News | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersJan 9 15:38 ET
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireJan 9 15:38 ET
Merck Downgraded by Truist to Hold Over Growth Concerns
Seeking AlphaJan 8 10:19 ET

Comments

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

103848509

Dec 10, 2024 07:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly

Jaguar8

Nov 20, 2024 08:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

SteadyBoomBeepBeep

Nov 20, 2024 06:18

$NewAmsterdam Pharma (NAMS.US)$ on watch